Carl Zeiss Meditec (OTCMKTS:CZMWY) Downgraded to Strong Sell Rating by Zacks Research

Posted by Brian Himes on Aug 13th, 2026

Zacks Research cut shares of Carl Zeiss Meditec (OTCMKTS:CZMWY – Free Report) from a hold rating to a strong sell rating in a research note released on Tuesday morning,Zacks.com reports.

Separately, UBS Group lowered shares of Carl Zeiss Meditec from a “neutral” rating to a “sell” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Check Out Our Latest Stock Analysis on Carl Zeiss Meditec

Carl Zeiss Meditec Trading Down 3.9%

Shares of Carl Zeiss Meditec stock opened at $34.41 on Tuesday. The stock has a 50-day simple moving average of $32.16 and a 200-day simple moving average of $31.08. Carl Zeiss Meditec has a 52-week low of $26.65 and a 52-week high of $55.94.

About Carl Zeiss Meditec

(Get Free Report)

Carl Zeiss Meditec AG is a global medical technology company headquartered in Jena, Germany. Founded in 2002 as a spin-off from the Carl Zeiss Group, the business leverages the parent company’s expertise in optics and precision engineering. Over the years, Carl Zeiss Meditec has grown through organic development and strategic acquisitions, becoming a recognized provider of innovative surgical and diagnostic solutions for eye care and microsurgery.

The company’s core offerings span two primary divisions: Ophthalmic Devices and Microsurgery.